Scott T. Tagawa, MD, MS, discusses fractionated dose 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-PresbyterianWeill Cornell Medical Center, discusses fractionated dose 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC).
Investigators are currently evaluating 177Lu-PSMA-617 in a dose-escalation study to determine the highest tolerable dose of the drug in patients with progressive mCRPC. So far, the phase I trial has not shown any significant acute or dose-limiting toxicities, says Tagawa. The low-grade toxicities observed were dry mouth and nausea, which were seen in other the prospective phase II study from Australia.
